Home > Drug- and Chemical Safety > Personal Background
Personal Background

Toxicology and Safety Pharmacology

Dr. Peter-Jürgen Kramer

Certified Expert in Toxicology GT/DGPT, EUROTOX Registered Toxicologist

  • Wide experience as leading toxicologist in the chemical and pharmaceutical industry,
    Global Head of Toxicology of Merck KGaA/Merck Serono
  • Long-standing lecturer in toxicology at universities in Germany and France
  • More than 2 decades official representative of Germany in expert groups of EU and OECD for the harmonisation of toxicological test methods, among others also for a drastic reduction of animal testing
  • Repeatedly nominated as member of expert committees (juries) of the German Ministry of Education and Research (BMBF), granting of public funding for research projects in the fields of 'Replacement of Animal Testing' and 'Innovation in Drug Development'.

Activities 2009/2010/2011

Publications (Selection)

  1. Are chromosomal aberration tests in vitro particulary prone to artificial findings?
    P.-J. Kramer, bga Schriften 1/1993
  2. Neurotoxicity Risk Assessment of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) as a Synthetic Impurity od Drugs
    Kramer, P.-J.; Caldwell, J.; Hofmann, A.; Tempel, P.; Weiße, G., Human & Experimental Toxicology 17:283-293 (1998)
  3. Genetic Toxicology
    Kramer, P.-J., J. Pharm. Pharmacol. 50:395-405 (1998)
  4. The polycyclic musk 7-acetyl-1,1,3,4,4,6-hexamethyl-1,2,3,4,-tetrahydronaphthaline lacks tumor initiating and promoting activity in rats exposed to human-relevant doses.
    P. Steinberg, I. Zschaler, E. Thom, M. Kuna, G. Wüst, A. Schäfer-Schwebel, R. Müller, P.-J. Kramer, G. Weiße, Arch. Toxicol. 75:562-568 (2001)
  5. Zur Bedeutung von genetischen Polymorphismen von Fremdstoff-metabolisierenden Enzymen in der Toxikologie. Stellungnahme der Beratungskommission der Sektion Toxikologie der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (DGPT)
    THOMAS SCHULZ, GISELA DEGEN, HEIDI FOTH, REGINE KAHL, PETER-JÜRGEN KRAMER, WERNER LILIENBLUM, DIETER SCHRENK, HERMANN SCHWEINFURTH, Umweltmed Forsch Prax 7 (4) 7A (2002)
  6. The REACH concept and its impact on toxicological sciences.
    J.G. Hengstler, H. Foth, R. Kahl, P.-J. Kramer, W. Lilienblum, T. Schulz, H. Schweinfurth, Toxicology 220:232-239 (2006)
  7. Nadine Zidek, Juergen Hellmann, Peter-Juergen Kramer and Philip Hewitt, Acute Hepatotoxicity: A predictive Model based on Focused Illumina Microarrays,Toxicological Sciences 99(1): 289-302 (2007)
  8. Non-clinical Study Reports (Module 4 EU-CTD) Guide to Drug Regulatory Affairs
    Klaus Olejniczak, Gerd Bode, Peter Kasper, Eckhard von Keutz, Peter-Jürgen Kramer, Editio Cantor 685-716 (2007)
  9. Hengstler JG, Foth H, Gebel T, Kramer PJ, Lilienblum W, Schweinfurth H, Völkel W, Wollin K-M, Gundert-Remy U. Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit Rev Toxicol. 2011 Apr;41(4):263-91.

Fraunhofer Institute for Toxicology and Experimental Medicine

Titelbild Jahresbericht

Research for human health is the focus of the Fraunhofer ITEM. We assess the risks of potentially harmful substances, investigate mechanisms of action and support our clients in the development of new medications. The most important target organs of our research are the lungs and airways.

More about us

News

News Report Oktober 2010 Deckblatt

The new News Report
October 2010 is available:
download PDF file